Targeted delivery using tissue-specific peptidomimetic ligands
Compositions and methods for tissue-specific targeted delivery of therapeutic agents through the use of tissue-specific peptidomimetic ligands are disclosed herein. The ligand comprises a composition of formula A-scaffold-A′ and one or more hydrophobic anchors covalently linked to the scaffold. The A and A′ compounds linked to the scaffold comprise monovalent peptidomimetic compounds wherein each monovalent peptidomimetic compound is selected from the group consisting of fragments IKs, GKs, IDs, GSs, GTs, VSs, TKs, KTs, ARs, KIs, KEs, AEs, GRs, YSs, IRs, and morpholino.
1. A tissue-specific targeting ligand for targeted delivery of therapeutic agents to a tissue comprising:
a composition of formula:
A-scaffold-A′,
wherein the scaffold is of the formula:
wherein the dotted lines represent the point of attachment to A and A′:
wherein A and A′ comprise monovalent peptidomimetic compounds, wherein each monovalent peptidomimetic compound has the following formula:
wherein the composition is incorporated into a lipid bilayer.
2. The targeted ligand of claim 1 , wherein the tissue is a cancerous cell, tissue or endothelium selected from pancreatic cancer, breast cancer, non-small cell lung carcinoma (NSCLC), pancreatic cancer vascular endothelium or NSCLC cancer vascular endothelium.
3. A method for synthesizing a small molecule complex for targeted delivery of therapeutic agents to a tissue, the method comprising:
coupling covalently two or more unprotected monovalent peptidomimetic compounds, of formulas A and A′, to a scaffold, wherein the scaffold is of the formula:
wherein the dotted lines represent the point of attachment to A and A′:
wherein A and A′ comprise monovalent peptidomimetic compounds, wherein each monovalent peptidomimetic compound has the following formula:
4. The method of claim 3 , wherein the tissue is a cancerous cell, tissue or endothelium selected from pancreatic cancer, breast cancer, non-small cell lung carcinoma (NSCLC), pancreatic cancer vascular endothelium or NSCLC cancer vascular endothelium.
5. A ligand-functionalized delivery system comprising:
a therapeutic agent carrier;
a tissue-specific targeting ligand for targeted delivery of therapeutic agents to a tissue comprising:
a composition of formula:
A-scaffold-A′,
wherein the scaffold is of the formula:
wherein the dotted lines represent the point of attachment to A and A′:
wherein A and A′ comprise monovalent peptidomimetic compounds, wherein each monovalent peptidomimetic compound has the following formula:
6. The ligand-functionalized delivery system of claim 5 , wherein the therapeutic agent carrier is a liposome.
7. The ligand-functionalized delivery system of claim 5 , wherein the therapeutic agent carrier is a cationic liposome having an internal lipid bilayer and an external lipid bilayer.
8. The ligand-functionalized delivery system of claim 5 , wherein the tissue is a cancerous cell, tissue or endothelium selected from pancreatic cancer, breast cancer, non-small cell lung carcinoma (NSCLC), pancreatic cancer vascular endothelium or NSCLC cancer vascular endothelium.
9. A method of delivering a payload to a target tissue comprising the steps of:
preparing a composition of formula:
A-scaffold-A′,
wherein the scaffold is of the formula:
wherein the dotted lines represent the point of attachment to A and A′:
wherein A and A′ comprise monovalent peptidomimetic compounds, wherein each monovalent peptidomimetic compound has the following formula:
incorporating the composition into a liposome that encapsulates a therapeutic agent to form a targeted liposome complex;
combining the targeted liposome complex with a reversible masking reagent; and
administering a therapeutically effective amount of the masked targeted liposome complex to a patient in need thereof.
10. The method of claim 9 , wherein the liposome is a bilamellar invaginated vesicle.
11. The method of claim 9 , wherein the reversible masking agent is a small neutral lipid with a molecular weight of about 500 Da or lower.
12. The method of claim 11 , wherein the small neutral lipid is n-dodecyl-beta-D-maltopyranoside.
13. The method of claim 12 , wherein the target tissue is a human pancreatic cancer.
14. The method of claim 9 , wherein the targeting ligands are at least one of compounds KB995, KB1005, KB1012, and KB1109.
15. The method of claim 14 , wherein the target tissue is a human breast cancer.
16. The method of claim 9 , wherein the targeting ligands are at least one of compounds KB1035, KB1036, KB1039, KB1063, KB1064, KB1066, and KB1067.
17. The method of claim 16 , wherein the target tissue is a human non-small cell lung carcinoma.
18. The method of claim 9 , wherein the targeting ligands are at least one of compounds KB1001, KB1003, KB1042, KB1051, KB1062, KB1096, KB1107, KB1108, and KB1029.
19. The method of claim 18 , wherein the target tissue is a human non-small cell lung carcinoma vascular endothelium.
20. The method of claim 9 , wherein the targeting ligand is compound KB1061.
21. The method of claim 20 , wherein the target tissue is a human pancreatic cancer vascular endothelium.
22. The method of claim 9 , wherein the targeting ligand is compound KB1023.
23. The method of claim 22 , wherein the anticancer therapeutic agent is a plasmid DNA encoding the antiangiogenic protein human thrombospondin-1 (TSP1).
24. The method of claim 20 , wherein the target tissue is a melanoma.
25. The method of claim 9 , wherein the targeting ligand is compound is at least one of KB1037, KB1109 and KB1123.
26. A method of isolating a peptidomimetic compound for binding to a target tissue comprising the steps of:
preparing a peptidomimetic library of compositions of formula:
A-scaffold-A′, wherein the scaffold is of the formula:
wherein the dotted lines represent the point of attachment to A and A′:
wherein A and A′ comprise monovalent peptidomimetic compounds, wherein each monovalent peptidomimetic compound has the following formula:
contacting a target tissue with the peptidomimetic compounds;
isolating those peptidomimetic compounds that binding specifically to the target tissue; and
characterizing the formula of the composition that bound specifically to the target tissue.
27. The method of claim 26 , wherein the method is a high throughput assay and the target tissue includes cells from a patient that are assayed directly following a dissociation step.
28. The method of claim 26 , wherein binding of the peptidomimetic library is screened by comparing binding between tumor cells and normal cells.
29. The method of claim 26 , wherein the peptidomimetic library is screened directly using time resolved fluorometry.
30. The method of claim 26 , wherein the peptidomimetic library is screened in a transfection based system.
31. The method of screening for a peptidomimetic compound that binds to a target tissue or cell comprising the steps of:
preparing a peptidomimetic library of compositions of formula:
A-scaffold-A′,
wherein the scaffold is of the formula:
wherein the dotted lines represent the point of attachment to A and A′:
wherein A and A′ comprise peptidomimetic compounds, wherein each monovalent peptidomimetic compound has the following formula:
mixing the peptidomimetic compounds with lipids to form liposomes;
contacting a target tissue with the peptidomimetic compounds;
isolating those peptidomimetic compounds that binding specifically to the target tissue; and
characterizing the formula of the composition that bound specifically to the target tissue.
32. A method of screening for a peptidomimetic compound that binds to a target tissue or cell comprising the steps of:
preparing a peptidomimetic library of compositions of formula:
A-scaffold-A′,
wherein the scaffold is of the formula:
wherein the dotted lines represent the point of attachment to A and A′:
wherein A and A′ comprise peptidomimetic compounds, wherein each monovalent peptidomimetic compound has the following formula:
mixing the peptidomimetic compounds with lipids to form liposomes, wherein the liposomes further comprise a nucleic acid for delivery to a cell;
contacting a target tissue with the peptidomimetic compounds;
isolating those peptidomimetic compounds that binding specifically to the target tissue; and
characterizing the formula of the composition that bound specifically to the target tissue.
33. The method of claim 32 , wherein the target tissue is defined further as cells in tissue culture.
34. The method of claim 32 , wherein the target tissue is defined further as cells in tissue culture and the cells are selected based on the effect of the nucleic acid on the cells.
35. The method of claim 32 , wherein the target tissue is defined further as cells in tissue culture, wherein the nucleic acid is a selective marker for negative or positive selection, expresses a selective marker for positive or negative selection, or expresses a detectable marker.